Navigation Links
Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
Date:6/2/2008

ty to penetrate new markets, the fixed price nature of contracts and cost overruns, the loss, cancellation or delay of contracts or amendments thereto, the ability to maintain existing customer relationships or enter into new ones, the company's sales cycle, the effects of exchange rate fluctuations, risks related to non-U.S. operations and other factors described in the company's filings with the Securities and Exchange Commission, including Quarterly Reports on Form 10-Q and the Annual Report on Form 10-K. No assurance can be given that the company will be able to realize the net service revenues included in backlog and verbal awards. Kendle believes that its aggregate backlog and verbal awards are not necessarily a meaningful indicator of future results. All information in this release is current as of June 2, 2008. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
2. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
3. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
4. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
5. Kendle to Present at the UBS Global Life Sciences Conference
6. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
7. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
8. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Kendle to Present at the Wachovia 2008 Healthcare Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 ... the addition of the "Global PDT Machine ...        (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... 2014 is a professional and in-depth study on ... ,The report provides a basic overview of the ...
(Date:6/1/2015)... Grove, IL (PRWEB) June 01, 2015 ... in developing and manufacturing of chiral stationary phases ... the options for its current and presenting solutions ... Service to its portfolio. This valuable addition to ... fast and effective advantage that can tackle projects ...
(Date:6/1/2015)... 1, 2015  Fennec Pharmaceuticals, Inc. (TSX: FRX, ... results from a poster presented today entitled, "Anti-tumor ... phase III trial of the efficacy of sodium ... cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." ... of Clinical Oncology (ASCO) 2015 Annual Meeting in ...
(Date:6/1/2015)... LANSING, Mich. , June 1, 2015  Neogen Corporation ... the assets of Sterling Test House, a leading commercial food ... and that the acquired laboratory will serve as a base ... . Sterling Test House was ... virtually all of the food safety and water quality testing ...
Breaking Biology Technology:Global PDT Machine Industry Report 2014 2Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Neogen acquires India food safety company 2
... Calif., April 21 /PRNewswire-FirstCall/-- Pharmacyclics,Inc. (Nasdaq: PCYC ... staff,deficiency letter on April 17, 2008 indicating that, ... for Pharmacyclics, common stock has closed,below the minimum ... for continued,inclusion on The Nasdaq Global Market under ...
... Per Share, SAN JOSE, Calif., April 21 ... provider of medical devices,for the minimally invasive treatment of ... quarter ended March 31, 2008., Net revenues for ... compared with $15.6 million for the first quarter of ...
... CALL AND WEBCAST SCHEDULED FOR WEDNESDAY, APRIL 30, ... NBIX ) announced today that the Company will report ... closes on Wednesday,April 30, 2008. Neurocrine will host a ... and provide a Company update Wednesday,afternoon, April 30, 2008 ...
Cached Biology Technology:VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 3VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 4VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 5VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 6VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 7Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results 2
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/22/2015)... , May 22, 2015 According ... by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, ... (Government and Utilities, Consumer and Home) - Global Forecast ... grow from $2.77 Billion in 2015 to $6.19 Billion ... Browse 79 market data Tables and   43 ...
(Date:5/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... LLC, a company engaged in biometric identification is an ... portion of the recently awarded TIES (Technical Information Engineering ... Army. 3D-ID LLC has a suite of ... and security agencies. Gino Pereira , ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... issue of Nature Genetics, is based on data from ... known genes, but also discovered ten new genes. Altogether ... 3.5 centimeters. The analysis produced some biologically insightful ... the microRNA let-7, which affects the regulation of other ...
... May 2008 Pediatric Academic Societies and Asian Society for ... obesity negatively impacts vascular endothelial function, which relates to ... the U.S. during the past 20 years and obesity ... incidence of obesity in children is also increasing and ...
... has swapped their comfortable offices for one of the ... a challenging field campaign that is seen as the ... mission CryoSat will be as accurate as possible. ... are currently in the middle of CryoSat Validation Experiment ...
Cached Biology News:How body size is regulated 2Study supports reason for concern in childhood and adolescent obesity 2Scientists endure Arctic for last campaign prior to CryoSat-2 launch 2Scientists endure Arctic for last campaign prior to CryoSat-2 launch 3
... (IC50 = 59.2 M). Formula: ... O 13 MolWeight: ... RT CAS: ... to 100 mM in DMSO IUPAC: ...
POU domain, class 2, transcription factor 2,...
NAP-2 (5C7)...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
Biology Products: